Over the last 7 days, the United States market has risen 2.1%, contributing to a notable 14% climb over the past year, with earnings expected to grow by 15% annually. In this favorable environment, ...

In Hazle Twp. on the end of a road in Humboldt Industrial Park, Michaels Stores wants to make its distribution center part of ...

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its ...

Merck’s stock fell 1.77% to $80.93 while the market gained, despite rising 5.26% over the past month. The company’s upcoming ...

Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its ...

The stock's fall snapped a four-day winning streak.

Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company's biggest ...

The partners will use UNP's AI-based macrocycle discovery platform to develop synthetic peptide therapeutics for multiple ...

Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

Have you or someone you love been diagnosed with Alzheimer’s disease? This clinical trial may be just what you.

A drug candidate Organon hailed as perhaps its “biggest potential opportunity” has flunked a phase 2 trial, prompting the company to end clinical development of the endometriosis prospect.